Trial Profile
A single arm, Phase II, Open-label Study to determine the efficacy of 100 mg twice daily oral dosing of midostaurin administered to patients with Aggressive Systemic Mastocytosis or Mast Cell Leukemia +/- an associated hematological clonal non-mast cell lineage disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Midostaurin (Primary)
- Indications Mast Cell Leukemia; Systemic mastocytosis
- Focus Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals Corporation
- 03 Dec 2021 Results from EXPLORER, PATHFINDER, D2201 and A2213 comparing the relative efficacy of avapritinib versus midostaurin for the treatment of AdvSM using matching-adjusted indirect comparison (MAIC) methodology, presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics
- 10 May 2020 Results (N=89), assessing quality of life and MC mediator related symptoms, published in the Journal of Allergy and Clinical Immunology
- 19 Jun 2018 Status changed from active, no longer recruiting to completed.